title: Hydroxymatairesinol and its mammalian metabolite enterolactone reduce the growth and metastasis of subcutaneous AH109A hepatomas in rats.
abstract: Both epidemiological and experimental evidence is accumulating to show that a lignan-rich diet may reduce the risk of human breast cancer. Possible anti-cancer effects of dietary lignans on hepatomas or hepatoma cells have not been the topic of earlier studies. In the present study, we examined the effect of 7-hydroxymatairesinol (HMR) and its mammalian metabolite, enterolactone (ENL), on AH109A hepatoma cell proliferation and invasion in vitro. HMR and ENL inhibited the proliferation and invasion of AH109A hepatoma cells in vitro. The 50% inhibitory concentration (IC50) of hepatoma cell proliferation was lower for ENL (10 microM) than HMR (> 200 microM). Likewise, IC50 of hepatoma cell invasion was lower for ENL (9 microM) than HMR (144 microM). ENL suppressed hepatoma cell proliferation by accumulating cells in G1 phase and elongating doubling time of these cells, and by increasing the rate of apoptosis. Subsequently, we investigated in vivo the effect of dietary HMR and ENL on growth and metastasis of AH109A hepatomas in rats. Both of these compounds reduced the growth and metastasis of solid AH109A hepatomas in rats. These in vitro and in vivo findings suggest that HMR has inhibitory activities on tumor growth and metastasis in the hepatoma-bearing rats, and that this anti-tumor effect is mediated at least partially by ENL, a metabolite of HMR.
authors.affiliation: Department of Applied Biological Science, Tokyo Noko University, Waiwaicho 3-5-8, Fuchu, Tokyo 183-8509, Japan.
authors.forename: Daiki
authors.initials: D
authors.lastname: Miura
authors.forename: Niina M
authors.initials: NM
authors.lastname: Saarinen
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Miura
authors.forename: Risto
authors.initials: R
authors.lastname: Santti
authors.forename: Kazumi
authors.initials: K
authors.lastname: Yagasaki
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D020128:Inhibitory Concentration 50; D017705:Lignans / Q000494:pharmacology*; D008114:Liver Neoplasms, Experimental / Q000473:pathology*; D008297:Male; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D051381:Rats; D014407:Tumor Cells, Cultured
chemical_list: D017705:Lignans; C419306:hydroxymatairesinol; D015107:4-Butyrolactone; C029497:2,3-bis(3'-hydroxybenzyl)butyrolactone